- ECONOMIC IMPACT -

Latest update: 19 May 

The global economy is forecasted to return to pre-crisis levels by the end of 2021 or early 2022. 

The unemployment rate in OECD nations stood at 6.5% in March 2021, down from 6.6% in Feb 2021.

4.3%

The EU Commission has raised the Eurozone's economic growth forecast for 2021 to 4.3% from its earlier projection of 3.8%.

$289tn

Global debt declined by $1.7tn to $289tn in Q1 2021, for the first time in the last ten quarters, according to the Institute of International Finance.

Impact of Covid-19 on equity indices

- SECTOR IMPACT: PHARMA -

Latest update: 19 May

industry development

40x

CVS reported a 40x increase in the use of telemedicine and virtual services via its MinuteClinic division compared to pre-Covid-19.

280

Oncology trials continue to suffer the most disruption, with 280 recorded trials put on hold due to the Covid-19 pandemic.

drug development

The Covid-19 pandemic has created a massive global effort centred around finding effective therapeutics and vaccines.


While the development and commercialisation of a safe vaccine typically take at least several years to materialise, Pfizer/BioNTech Covid-19 has beaten that timeline by a considerable margin with the UK becoming the first market to approve the jab.


Vaccine candidates using classic technology will likely take at least 12-18 months to develop; however, timelines for DNA, mRNA or adenoviral vaccines are indeed shorter as multiple vaccines from Pfizer/BioNTech, Moderna and AstraZeneca now have demonstrated efficacy in the prevention of Covid-19.


Nevertheless, with pharmaceutical companies shifting their strategies to focus on the development of Covid-19-related assets, the non-Covid-19 drug development programmes have been brought to a temporary backseat.

Key pharma market developments

Share this article

Go to article: Home | Relinking the pharma supply chainGo to article: In this issueGo to article: ContentsGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: Datwyler Company Insight Go to article: DatwylerGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: ILC Dover Go to article: ButterworthGo to article: CommentGo to article: New Chinese Breakthrough Therapy designation attracts foreign companiesGo to article: Endometrial cancer patients expected to benefit from novel advancementsGo to article: Regulatory and strategic complications of marketing an oncology drug in AsiaGo to article: The biopharma revolution: navigating complexityGo to article: TRiBECA KnowledgeGo to article: PerkinElmerGo to article: In DepthGo to article: What’s in a drug name?Go to article: Improving care for rare diseases in IndiaGo to article: Focus on the patient, not the pillGo to article: Academic-industry collaborationGo to article: Rewriting the pharma supply chain for a post-pandemic world Go to article: Developing an oral Covid-19 vaccineGo to article: The Solubility Company - Company Insight Go to article: The Solubility companyGo to article: In DataGo to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article:  Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue